Piper Sandler Upgrades Medtronic to Overweight, but MDT Slips After Hugo Clearance
Piper Sandler raised Medtronic to Overweight with a $120 price target on the morning the FDA widened U.S. use of the Hugo surgical robot. The stock still closed 0.54% below Monday's close on lighter-than-usual volume.

Piper Sandler upgraded Medtronic plc (NYSE: MDT) to Overweight from Neutral on Nov. 17 and set a $120 price target, in pre-market trading (the session before the regular open). The same morning, at 6:00 a.m. ET, the company said the FDA had cleared the Hugo robotic-assisted surgery system for general surgery procedures.
Two upbeat items, no lift for the shares
Medtronic closed at $102.32, down 0.54% from Monday's close of $102.88, despite the upgrade and the clearance. Volume was below its recent average, and the stock was already lower before the regular session began. It is not clear what reasons Piper Sandler gave for the upgrade, or whether it tied the change to Hugo.
Shares drifted lower and closed near the session low
In pre-market trading the stock was at $102.03 at 9:29 a.m., 0.92% below Monday's after-hours close, on only 9,211 shares. It is not clear whether the decline began before the 6:00 a.m. release.
The regular session ranged from $102.12 to $103.84, and the close was close to the bottom of that band. About 4.10 million shares traded, against a 10-day average of about 7.09 million. In after-hours trading (after the 4 p.m. close) the stock was at $102.74, up 0.41%, on 130,555 shares.
Before the news, the stock had gained 10.9% over the sessions from Oct. 19 to Nov. 16. It hit a low of $92.67 on Oct. 19 and a high of $106.20 on Nov. 5. Its biggest daily gain in that stretch was 6.15% on Nov. 4, and its biggest drop was 2.90% on Nov. 6. The last five closes ranged from $100.99 to $102.88.
A $131.6 billion company that a single note barely moved
Medtronic has a market value of about $131.6 billion and a float (shares available for public trading) of about 1.27 billion. A rating change from one firm is small against that base, and the Hugo clearance came with no sales figures attached to it.
What the Hugo clearance adds
The clearance covers all upper abdominal general surgery procedures, including cholecystectomy (gallbladder removal), gastric bypass, ventral hernia repair and small bowel resection. Inguinal hernia repair and appendectomy were also cleared. The company said these procedures total about 3.5 million surgeries a year in the U.S., more than half of all soft-tissue procedures.
According to the release, the clearance widens Hugo's use at U.S. hospitals beyond urology. Other points from the company:
- Hugo procedure growth worldwide is running at more than two times the robotic surgery market.
- Hugo is on track to surpass 50,000 procedures by the end of Medtronic's fiscal year.
- Outside the U.S., general surgery is now the fastest-growing area for Hugo, ahead of urology and gynecology.
On Monday the company said it intends to acquire Contego Medical, a privately held company, to expand access to carotid therapies. The shares closed Monday up 0.02%.
What to watch next
- Nov. 24: Medtronic said it will report financial results on Tuesday, Nov. 24.
Bottom line
An upgrade and an FDA clearance on the same morning left Medtronic about half a percent lower at the close, on lighter trading. The clearance opens a much larger set of U.S. procedures to Hugo, and the Nov. 24 report is the company's next scheduled update.
This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.
This article is for informational purposes only and is not investment advice.




